In another more extensive study of patients with acute coronary syndromes (ACS; 47 subjects completed the protocol), 5 weekly injections of a recombinant HDL-like particle (designated ETC-216) containing ApoA-Imilan led to a reduction in coronary atheroma volume by 4.2% compared to the baseline level measured by intravascular ultrasound. The gene discussed is APOA1; the disease is acute coronary syndrome.